Atay Kadri, Eyvazov Hayyam, Bozcan Selma, Eşkazan Tuğçe, Demir Nurhan, Hatemi İbrahim, Erzin Yusuf, Çelik Aykut Ferhat
Department of Gastroenterology, İstanbul University Cerrahpaşa School of Medicine, İstanbul, Turkey.
Department of Gastroenterology, İstanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, İstanbul, Turkey.
Turk J Gastroenterol. 2019 Jul;30(7):599-604. doi: 10.5152/tjg.2019.17291.
BACKGROUND/AIMS: The aim of the present study was to compare the demographic features and long-term outcomes of patients with inflammatory bowel disease (IBD) with or without ankylosing spondylitis (AS).
Among 1640 IBD (Crohn's disease and ulcerative colitis), 76 patients with IBD+AS were identified. The study group consisted of 76 patients with IBD with synchronous AS. The control group consisted of patients with only IBD, and those were selected according to their registry sequence number being the previous and next case to the diseased case with IBD+AS. The primary endpoint was to compare the rate of intestinal resections between both groups (IBD vs. IBD+AS).
Among 76 patients with IBD+AS, 52 (68%) first presented with IBD, 11 (15%) with AS, and the remaining 13 (17%) had both diagnoses at the same time. The mean follow-up time was significantly longer in patients with IBD+AS (43.4 vs. 27.8 months; p=0.01). Twenty-two percent of patients with IBD and 14% of those with IBD+AS had an intestinal resection (p=NS). Biologic and systemic corticosteroid treatments were significantly more common among patients with IBD+AS (32% vs. 7% for biologics, p<0.0001 and 44% vs. 28% for corticosteroids, p=0.042). Age-sex-adjusted regression analysis for both groups disclosed IBD duration as the only independent predictor for resection (R2=0.178; p=0.016).
The present study shows that up to 5% of patients with IBD may have AS. Patients with IBD+AS do not have a worse disease outcome than solo patients with IBD.
背景/目的:本研究旨在比较合并或不合并强直性脊柱炎(AS)的炎症性肠病(IBD)患者的人口统计学特征和长期预后。
在1640例IBD(克罗恩病和溃疡性结肠炎)患者中,确定了76例IBD+AS患者。研究组由76例同时患有IBD和AS的患者组成。对照组由仅患有IBD的患者组成,这些患者根据其登记序列号选择,为患有IBD+AS的患病病例的前一个和后一个病例。主要终点是比较两组(IBD与IBD+AS)之间的肠道切除术发生率。
在76例IBD+AS患者中,52例(68%)首次表现为IBD,11例(15%)表现为AS,其余13例(17%)同时有两种诊断。IBD+AS患者的平均随访时间显著更长(43.4个月对27.8个月;p=0.01)。22%的IBD患者和14%的IBD+AS患者进行了肠道切除术(p=无显著差异)。生物制剂和全身性皮质类固醇治疗在IBD+AS患者中显著更常见(生物制剂分别为32%对7%,p<0.0001;皮质类固醇分别为44%对28%,p=0.042)。两组的年龄-性别调整回归分析显示,IBD病程是切除术的唯一独立预测因素(R2=0.178;p=0.016)。
本研究表明,高达5%的IBD患者可能患有AS。IBD+AS患者的疾病预后并不比单纯IBD患者更差。